CRISPR Therapeutics (NasdaqGM:CRSP) has set new 2026 milestones, including planned regulatory submissions for Casgevy in patients aged 5 to 11. The company outlined progress in several clinical ...

Last year, a ten-month-old baby in the US was the first person in the world to have their rare genetic disease effectively ...

UC San Diego researchers have created a new system that reveals specific categories of potentially risky mutations resulting from CRISPR edits. This high magnification image reveals CRISPR-based DNA ...

CRISPR Therapeutics AG reported a Q1 net loss of $136m, but maintains a strong cash position with $1.86bn in cash and marketable securities. Casgevy, a gene therapy for Sickle Cell Disease, has seen ...

One of the most well-known versions of the gene-editing tool CRISPR may not work in a large proportion of the population, according to recent research out of Stanford University in California. CRISPR, ...

Crispr Therapeutics (CRSP) is downgraded to "Hold" as current valuation already reflects optimism for CTX310 Phase I results and pipeline progress. Intellia Therapeutics (NTLA) maintains a "Buy" ...

Why CRISPR Therapeutics Is On Investors’ Radar Today CRISPR Therapeutics (CRSP) has attracted fresh attention after recent trading left the stock around $54.65, with performance mixed over the past ...

Oceanic ecosystems are increasingly threatened by global warming, which causes coral bleaching, species migration and, ...

CRISPR Therapeutics CRSP and Intellia Therapeutics NTLA are leading developers of therapies that utilize the Nobel Prize-winning CRISPR/Cas9 gene editing technology. While CRSP is the first and only ...

A Swiss biotechnology company said it has used the gene-editing technology CRISPR to treat a patient with a dangerous blood disease called beta thalassemia, marking the technology’s first trial run by ...